Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150866 | 0.85 | HPGD (0.50) | HPGDHTTALDH1A1MEN1KMT2A | |
| SCHEMBL4154038 | 0.83 | HPGD (0.49) | HPGDHTTALDH1A1MEN1KMT2A | |
| SCHEMBL7457513 | 0.81 | HPGD (0.56) | HPGDHTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL7457510 | 0.78 | HPGD (0.49) | HPGDHTTALDH1A1SMN1; SMN2GLA | |
| SCHEMBL324878 | 0.77 | ALDH1A1 (0.63) | HPGDALDH1A1SMN1; SMN2GLA | |
| SCHEMBL29175534 | 0.77 | SMN1; SMN2 (0.49) | HPGDHTTALDH1A1SMN1; SMN2GLA | |
| SCHEMBL10013747 | 0.73 | HTT (0.72) | HPGDHTTALDH1A1SMN1; SMN2GAA | |
| SCHEMBL7121916 | 0.73 | SMN1; SMN2 (0.77) | HPGDHTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL9792238 | 0.72 | HPGD (0.55) | HPGDALDH1A1SMN1; SMN2GLANPSR1 | |
| SCHEMBL12569441 | 0.71 | PKM (0.60) | HTTALDH1A1SMN1; SMN2GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | US | disclosed |
| EP-1718653-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | Ligand Pharmaceuticals Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082909-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | NR3C1, NR3C2, MC2R | HPGD 272/4885HTT 4858/4885ALDH1A1 1465/4885 |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | NR3C1, NR3C2, MC2R | HPGD 272/4885HTT 4858/4885ALDH1A1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.